Citrine Angels: The 2023 Year in Review
2023 was a banner year for Citrine Angels! So many exciting opportunities have come our way, and we couldn’t have done it without all of you – members, sponsors, community supporters, and entrepreneurs alike.
We gained more than 25 new members, with our membership total surpassing 60 women. Our members come from as far away as Oregon and as close by as Washington, DC. Each and every one is a dynamic woman investor who contributes to our network by participating in pitch meetings and social events, helping lead Citrine behind the scenes, and spreading word of our commitment to lifting up women in business.
We hit a major milestone this year when we surpassed $1 million invested. In fact, we steamrolled past it by investing over $400,000. These dollars are closing the gap in the amount of venture funding received by male vs female founders, and we couldn’t be more excited about these investments.
Our new portfolio companies include:
- Elitone, whose external devices aid the pelvic floor and calm an overactive bladder
- Mocktail Club, which provides delicious and healthy alcohol-free beverages
- Mosie Baby, whose at-home insemination kit is the first of its kind to receive FDA approval
- NopSec, which works with a company’s SecOps and ITOps teams and infrastructure to reduce organization exposure
- OxiWear, the first wearable for continuous SPO2 monitoring
- Relavo, a safer and more accessible home dialysis system
As we’ve gained this traction, word has gotten out about our success and the media has taken notice! We led DC Startup Week’s “Women Investing in Women” panel, and were featured in pieces in WTOP and Technical.ly. Fast Company gave us a shoutout in describing women’s angel investing groups as the “meetup of the future.” We were even in a documentary!
We expect even greater things for 2024, and we hope you’ll join us on our journey! Check out our guidelines for joining as a member, becoming a sponsor, or applying for funding. We can’t wait to see what you have in store.